Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 846

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001

Open access
Brown, Paul D., Gondi, Vinai, Pugh, Stephanie, Tome, Wolfgang A., Wefel, Jeffrey S., Armstrong, Terri S., Bovi, Joseph A., Robinson, Cliff, Konski, Andre, Khuntia, Deepak, Grosshans, David, Benzinger, Tammie L. S., Bruner, Deborah, Gilbert, Mark R., Roberge, David, Kundapur, Vijayananda, Devisetty, Kiran, Shah, Sunjay, Usuki, Kenneth, Anderson, Bethany Marie, Stea, Baldassarre, Yoon, Harold, Li, Jing, Laack, Nadia N., Kruser, Tim J., Chmura, Steven J., Shi, Wenyin, Deshmukh, Snehal, Mehta, Minesh P., Kachnic, Lisa A., for NRG Oncology·2020·Journal of Clinical Oncology

Abstract

PURPOSE: Radiation dose to the neuroregenerative zone of the hippocampus has been found to be associated with cognitive toxicity. Hippocampal avoidance (HA) using intensity-modulated radiotherapy during whole-brain radiotherapy (WBRT) is hypothesized to preserve cognition. METHODS: This phase III trial enrolled adult patients with brain metastases to HA-WBRT plus memantine or WBRT plus memantine. The primary end point was time to cognitive function failure, defined as decline using the reliable change index on at least one of the cognitive tests. Secondary end points included overall survival (OS), intracranial progression-free survival (PFS), toxicity, and patient-reported symptom burden. RESULTS: Between July 2015 and March 2018, 518 patients were randomly assigned. Median follow-up for alive patients was 7.9 months. Risk of cognitive failure was significantly lower after HA-WBRT plus memantine versus WBRT plus memantine (adjusted hazard ratio, 0.74; 95% CI, 0.58 to 0.95; P = .02). This difference was attributable to less deterioration in executive function at 4 months (23.3% v 40.4%; P = .01) and learning and memory at 6 months (11.5% v 24.7% [ P = .049] and 16.4% v 33.3% [ P = .02], respectively). Treatment arms did not differ significantly in OS, intracranial PFS, or toxicity. At 6 months, using all data, patients who received HA-WBRT plus memantine reported less fatigue ( P = .04), less difficulty with remembering things ( P = .01), and less difficulty with speaking ( P = .049) and using imputed data, less interference of neurologic symptoms in daily activities ( P = .008) and fewer cognitive symptoms ( P = .01). CONCLUSION: HA-WBRT plus memantine better preserves cognitive function and patient-reported symptoms, with no difference in intracranial PFS and OS, and should be considered a standard of care for patients with good performance status who plan to receive WBRT for brain metastases with no metastases in the HA region.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.19.02767

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 846

Metadata

Authors
Brown, P. D., Gondi, V., Pugh, S., Tome, W. A., Wefel, J. S., Armstrong, T. S., Bovi, J. A., Robinson, C., Konski, A., Khuntia, D., Grosshans, D., Benzinger, T. L. S., Bruner, D., Gilbert, M. R., Roberge, D., Kundapur, V., Devisetty, K., Shah, S., Usuki, K., Anderson, B. M., Stea, B., Yoon, H., Li, J., Laack, N. N., Kruser, T. J., Chmura, S. J., Shi, W., Deshmukh, S., Mehta, M. P., Kachnic, L. A., & Oncology, F. N.
Venue
Journal of Clinical Oncology
Published
2020-04-01
Volume
38
Issue
10
Pages
1019-1029
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3005704292
Cited by
846
References
33
FWCI
61.08
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. https://app.cochat.ai/papers/10.1200/jco.19.02767
The paper
Brown, P. D., Gondi, V., Pugh, S., Tome, W. A., Wefel, J. S., Armstrong, T. S., Bovi, J. A., Robinson, C., Konski, A., Khuntia, D., Grosshans, D., Benzinger, T. L. S., Bruner, D., Gilbert, M. R., Roberge, D., Kundapur, V., Devisetty, K., Shah, S., Usuki, K., . . . Oncology, F. N. (2020). Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. Journal of Clinical Oncology. https://doi.org/10.1200/jco.19.02767

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.